DK1696909T3 - Benzothiazolderivater til behandling af diabetes - Google Patents
Benzothiazolderivater til behandling af diabetesInfo
- Publication number
- DK1696909T3 DK1696909T3 DK04787110T DK04787110T DK1696909T3 DK 1696909 T3 DK1696909 T3 DK 1696909T3 DK 04787110 T DK04787110 T DK 04787110T DK 04787110 T DK04787110 T DK 04787110T DK 1696909 T3 DK1696909 T3 DK 1696909T3
- Authority
- DK
- Denmark
- Prior art keywords
- unsubstituted
- substituted
- treatment
- benzothiazole derivatives
- group
- Prior art date
Links
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical class C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 title abstract 2
- 206010012601 diabetes mellitus Diseases 0.000 title abstract 2
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 abstract 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 2
- 206010022489 Insulin Resistance Diseases 0.000 abstract 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 abstract 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 abstract 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 abstract 2
- 201000010065 polycystic ovary syndrome Diseases 0.000 abstract 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 125000003277 amino group Chemical group 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 201000001421 hyperglycemia Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 125000000714 pyrimidinyl group Chemical group 0.000 abstract 1
- 125000003107 substituted aryl group Chemical group 0.000 abstract 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03102740 | 2003-09-12 | ||
| PCT/EP2004/052090 WO2005025567A1 (fr) | 2003-09-12 | 2004-09-08 | Derives de benzothiazole pour le traitement du diabete |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1696909T3 true DK1696909T3 (da) | 2008-01-02 |
Family
ID=34306921
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK04787110T DK1696909T3 (da) | 2003-09-12 | 2004-09-08 | Benzothiazolderivater til behandling af diabetes |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20070088017A1 (fr) |
| EP (1) | EP1696909B1 (fr) |
| JP (1) | JP5021307B2 (fr) |
| AT (1) | ATE378047T1 (fr) |
| AU (1) | AU2004271740B2 (fr) |
| CA (1) | CA2534314C (fr) |
| CY (1) | CY1107820T1 (fr) |
| DE (1) | DE602004010178T2 (fr) |
| DK (1) | DK1696909T3 (fr) |
| ES (1) | ES2297494T3 (fr) |
| HR (1) | HRP20070527T3 (fr) |
| IL (1) | IL174250A (fr) |
| NO (1) | NO20061600L (fr) |
| PL (1) | PL1696909T3 (fr) |
| PT (1) | PT1696909E (fr) |
| SI (1) | SI1696909T1 (fr) |
| WO (1) | WO2005025567A1 (fr) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7838522B2 (en) * | 2004-11-17 | 2010-11-23 | Ares Trading S.A. | Benzothiazole formulations and use thereof |
| BRPI0613042A2 (pt) | 2005-07-15 | 2010-12-14 | Serono Lab | inibidores de jnk para o tratamento de endometriose |
| KR20080044836A (ko) | 2005-07-15 | 2008-05-21 | 라보라뚜와르 세로노 에스. 에이. | 자궁내막증 치료용 ｊｎｋ 억제제 |
| EP2258357A3 (fr) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenèse avec inhibiteur de l'acetylcholinestérase |
| CA2620333A1 (fr) | 2005-08-26 | 2007-03-01 | Braincells, Inc. | Neurogenese par modulation du recepteur muscarinique |
| JP2009512711A (ja) | 2005-10-21 | 2009-03-26 | ブレインセルス，インコーポレイティド | Ｐｄｅ阻害による神経新生の調節 |
| US20070112017A1 (en) | 2005-10-31 | 2007-05-17 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| EP2382975A3 (fr) | 2006-05-09 | 2012-02-29 | Braincells, Inc. | Neurogénèse par modulation d'angiotensine |
| PT2054049E (pt) | 2006-08-24 | 2016-06-02 | Univ Tennessee Res Found | Acilanilidas substituídas e métodos de utilização das mesmas |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| EP2137173A2 (fr) * | 2007-04-17 | 2009-12-30 | Laboratoires Serono SA | Procédé de préparation de pipérazine-benzothiazoles |
| UA100527C2 (en) * | 2007-10-10 | 2013-01-10 | Астразенека Аб | Benzothiazoles as ghrelin receptor modulators |
| WO2010099217A1 (fr) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation de neurogenèse à l'aide de combinaisons de d-cyclosérine |
| US10987334B2 (en) | 2012-07-13 | 2021-04-27 | University Of Tennessee Research Foundation | Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs) |
| IN2015DN01046A (fr) | 2012-07-13 | 2015-06-26 | Gtx Inc | |
| US10258596B2 (en) | 2012-07-13 | 2019-04-16 | Gtx, Inc. | Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS) |
| US9622992B2 (en) | 2012-07-13 | 2017-04-18 | Gtx, Inc. | Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs) |
| US9969683B2 (en) | 2012-07-13 | 2018-05-15 | Gtx, Inc. | Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS) |
| US10314807B2 (en) | 2012-07-13 | 2019-06-11 | Gtx, Inc. | Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS) |
| US9744149B2 (en) | 2012-07-13 | 2017-08-29 | Gtx, Inc. | Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs) |
| WO2014114186A1 (fr) * | 2013-01-24 | 2014-07-31 | 山东亨利医药科技有限责任公司 | Inhibiteurs de la jnk |
| WO2017025980A2 (fr) * | 2015-08-12 | 2017-02-16 | Shoolineuniversity Of Biotechnology And Management Sciences | Nouveaux dérivés de benzothiazole ayant une activité biologique améliorée |
| CN115887434B (zh) * | 2022-11-23 | 2024-12-24 | 四川大学 | 具有抗氧化作用的药物用于制备治疗多囊卵巢综合征药物的用途 |
| US11970467B1 (en) | 2023-10-13 | 2024-04-30 | King Faisal University | N′-(2-naphthoyloxy)-2-(benzo[d]oxazol-2-yl)acetimidamide as an antimicrobial compound |
| US11905260B1 (en) | 2023-10-13 | 2024-02-20 | King Faisal University | N′-(1-naphthoyloxy)-2-(benzo[d]oxazol-2-yl)acetimidamide as an antimicrobial compound |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1176269A (fr) * | 1981-03-02 | 1984-10-16 | Kazimir Sestanj | Derives de n-naphtoylglycine |
| US4927831A (en) * | 1988-10-20 | 1990-05-22 | American Home Products | Spiro-isoquinoline-pyrrolidine tetrones and analogs thereof useful as aldose reductase inhibitors |
| US6559188B1 (en) * | 1999-09-17 | 2003-05-06 | Novartis Ag | Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes |
| EP1110957A1 (fr) * | 1999-12-24 | 2001-06-27 | Applied Research Systems ARS Holding N.V. | Dérivés de benzazole et leur utilisation comme modulateurs de JNK |
| US7776854B2 (en) * | 2001-12-07 | 2010-08-17 | Merck Serono Sa | Benzazole derivatives for the treatment of scleroderma |
| RS51407B (sr) * | 2002-04-25 | 2011-02-28 | Laboratoires Serono Sa | Piperazinski benzotijazoli kao agensi za lečenje cerabralnih ishemičnih poremećaja ili poremećaja cns |
-
2004
- 2004-09-08 CA CA2534314A patent/CA2534314C/fr not_active Expired - Fee Related
- 2004-09-08 ES ES04787110T patent/ES2297494T3/es not_active Expired - Lifetime
- 2004-09-08 WO PCT/EP2004/052090 patent/WO2005025567A1/fr not_active Ceased
- 2004-09-08 DE DE602004010178T patent/DE602004010178T2/de not_active Expired - Lifetime
- 2004-09-08 DK DK04787110T patent/DK1696909T3/da active
- 2004-09-08 AT AT04787110T patent/ATE378047T1/de active
- 2004-09-08 JP JP2006525827A patent/JP5021307B2/ja not_active Expired - Fee Related
- 2004-09-08 US US10/571,291 patent/US20070088017A1/en not_active Abandoned
- 2004-09-08 HR HR20070527T patent/HRP20070527T3/xx unknown
- 2004-09-08 SI SI200430550T patent/SI1696909T1/sl unknown
- 2004-09-08 PL PL04787110T patent/PL1696909T3/pl unknown
- 2004-09-08 EP EP04787110A patent/EP1696909B1/fr not_active Expired - Lifetime
- 2004-09-08 PT PT04787110T patent/PT1696909E/pt unknown
- 2004-09-08 AU AU2004271740A patent/AU2004271740B2/en not_active Ceased
-
2006
- 2006-03-12 IL IL174250A patent/IL174250A/en not_active IP Right Cessation
- 2006-04-07 NO NO20061600A patent/NO20061600L/no not_active Application Discontinuation
-
2007
- 2007-12-04 CY CY20071101543T patent/CY1107820T1/el unknown
-
2013
- 2013-10-08 US US14/048,690 patent/US20140107116A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| PL1696909T3 (pl) | 2008-04-30 |
| SI1696909T1 (sl) | 2008-02-29 |
| PT1696909E (pt) | 2007-12-21 |
| AU2004271740B2 (en) | 2010-10-28 |
| ATE378047T1 (de) | 2007-11-15 |
| IL174250A0 (en) | 2006-08-01 |
| CA2534314C (fr) | 2012-11-13 |
| WO2005025567A1 (fr) | 2005-03-24 |
| JP2007505083A (ja) | 2007-03-08 |
| DE602004010178D1 (de) | 2007-12-27 |
| DE602004010178T2 (de) | 2008-09-11 |
| CY1107820T1 (el) | 2013-06-19 |
| NO20061600L (no) | 2006-04-07 |
| EP1696909A1 (fr) | 2006-09-06 |
| CA2534314A1 (fr) | 2005-03-24 |
| AU2004271740A1 (en) | 2005-03-24 |
| US20140107116A1 (en) | 2014-04-17 |
| US20070088017A1 (en) | 2007-04-19 |
| IL174250A (en) | 2011-01-31 |
| HK1096594A1 (en) | 2007-06-08 |
| EP1696909B1 (fr) | 2007-11-14 |
| ES2297494T3 (es) | 2008-05-01 |
| JP5021307B2 (ja) | 2012-09-05 |
| HRP20070527T3 (en) | 2007-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1107820T1 (el) | Παραγωγα βενζοθειαζολιου για την θεραπευτικη αντιμετωπιση του διαβητη | |
| ATE557030T1 (de) | Kondensiertes heterocyclisches derivat, dieses enthaltende medizinische zusammensetzung und deren medizinische verwendung | |
| NO20080789L (no) | 1,4-benzotiazepin 1,1-dioksidderivater, fremgangsmate for fremstilling derav, medikamenter inneholdende denne forbindelsen og anvendelse derav som et hypolipid | |
| DE60325740D1 (de) | Verwendung von protein-kinase-n-beta | |
| WO2010045303A3 (fr) | Dérivés de pyrrolidine, de pipéridine et de pipérazine et leurs méthodes d'utilisation | |
| BRPI0407620A (pt) | derivados de arila e heteroarila substituìdos como moduladores do metabolismo da glicose e a profilaxia e tratamento de seus distúrbios | |
| CY1112466T1 (el) | ΠΥΡΡΟΛΙΔΙΝΟΝΕΣ ΥΠΟΚΑΤΕΣΤΗΜΕΝΕΣ ΜΕ ΠΙΠΕΡΙΔΙΝΥΛΙΟ ΩΣ ΑΝΑΣΤΟΛΕΙΣ ΤΗΣ 11-β-ΥΔΡΟΞΥΣΤΕΡΟΕΙΔΟΥΣ ΑΦΥΔΡΟΓΟΝΑΣΗΣ 1 | |
| BRPI0412689A (pt) | derivados de heteroarila e arila fundida como moduladores de metabolismo e a profilaxia e tratamento de distúrbios relacionados a ele | |
| EA200870460A1 (ru) | Производные циклогексилпиразол-лактама в качестве ингибиторов 11-бета-гидроксистероиддегидрогеназы 1 | |
| PA8566201A1 (es) | Nuevos derivados de piridina y quinolina | |
| EA200870470A1 (ru) | Ингибиторы 11-бета-гидроксистероид дегидрогеназы 1 | |
| NO20063431L (no) | 3-(4-Benzyloksyfenyl)propionsyrederivater | |
| NO20080728L (no) | Nye 1,4-benzotiazepin-1,1-dioksidderivater som har forbedrede egenskaper, fremgangsmate for fremstilling derav, medikamenter inneholdende nevnte forbindelsene og anvendelse derav | |
| ATE551997T1 (de) | Sulfonamid-derivate zur behandlung von diabetes | |
| BRPI0911035B8 (pt) | ativadores de pirrolidinona glicoquinase | |
| NO20065868L (no) | Substituerte aryl- og heteroarylderivater som metabolisme- og profylkasemodulatorer og behandling av forstyrrelser forbundet med dette | |
| NO20054713D0 (no) | C-glycosidderivater og salter derav | |
| ATE455772T1 (de) | Alkinylarylcarbonsäureamide | |
| NO20061614L (no) | Benzimidazolacetonitriler | |
| DK1470102T3 (da) | Substituerede methylenamidderivater som modulatorer af proteintyrosinphosphataser (PTPS) | |
| MY152172A (en) | Therapeutic agent for diabetes | |
| BR0313377A (pt) | Bifenilcarnboxamidas substituìdas por n-aril piperidina como inibidores de secreção de apolipoproteìna b | |
| NO20061599L (no) | Benzoksazol acetonitriler | |
| IL176171A0 (en) | N-aryl piperidine substituted biphenylcarboxamides | |
| DK1656139T3 (da) | Aryldicarboxamider |